About / Investor Updates
Investor Updates
Updates are shared periodically to reflect key milestones, partnerships, and clinical progress
Corporate Update
"Fierce Healthcare Names SpotitEarly a “Fierce 15” Company of 2026"
Mar 9 2026
We’re proud to share that SpotitEarly has been named a 2026 Fierce 15 company by Fierce Healthcare, recognizing the most innovative private healthcare companies shaping the future of the industry.
Clinical Update
"SpotitEarly Announces Strategic Partnership With Fox Chase Cancer Center, Bolstering the Validity of Its Breakthrough Early Cancer Detection Technology"
Jan 22 2026
This collaboration is expected to generate high-quality clinical evidence supporting regulatory pathways and long-term commercialization in the U.S. market.
Clinical Update
.png)
“SpotitEarly and Hackensack Meridian Health Partner to Advance Early Cancer Detection with Cancer-Sniffing Dogs” (BusinessWire)
Sept 30 2025
SpotitEarly announced a research partnership with Hackensack Meridian Health to launch the PINK Study, a 2,000-participant U.S. clinical trial focused on breath-based breast-cancer screening.
corporate Update
Clinical Update
.png)
“New Study Indicates SpotitEarly Detects Multiple Cancers Early by Using AI-Trained Canines and Breath Samples” (PR Newswire)
Dec 04 2024
SpotitEarly announced breakthrough results from its multicancer “Rainbow Study,” showing that its breath-based test combining trained dogs and AI can detect cancers such as breast, lung, prostate, and colorectal with over 94% accuracy.
Annoncements
Academic Engagement: NYU Langone Health
Our CEO, Dr. Shlomi Madar, was invited to present at the NYU Langone Health Institute for Systems Genetics as part of its Nano Seminar Series. During the seminar, Dr. Madar presented SpotitEarly’s Bio-AI hybrid approach to breath-based cancer screening, explaining how trained canines and the LUCID platform work together to identify cancer signatures in breath samples. He also shared the journey from early research through our current U.S. clinical studies.
Academic Spotlight: Rutgers University
Dr. Madar was also invited to deliver a seminar at the Ernest Mario School of Pharmacy at Rutgers University, part of Rutgers Biomedical and Health Sciences. The invitation came from Tamara Minko, Distinguished Professor and Department Chair, a member of the Rutgers Cancer Institute of New Jersey and author of more than 400 peer-reviewed publications in journals including Nature Nanotechnology and Cancer Research.
SpotitEarly at the HITLAB Innovators Summit
Our CEO, Dr. Shlomi Madar, will present at the HITLAB Innovators Summit during NYC Health Innovation Week in New York City. The summit brings together leaders across healthcare, technology, and venture capital, providing an opportunity to showcase SpotitEarly’s technology to industry decision-makers and potential partners.
Upcoming Events
May
5
Innovators Summit
Microsoft Tech Center, Time Square
March
17
BIRD reception
Washington, D.C.